Financial Comparison: Notable Labs (NASDAQ:NTBL) versus COMPASS Pathways (NASDAQ:CMPS)

Notable Labs (NASDAQ:NTBL) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Valuation & Earnings

This table compares Notable Labs and COMPASS Pathways’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Notable Labs	$310,000.00	4.55	-$11.26 million	N/A	N/A
COMPASS Pathways	N/A	N/A	-$118.46 million	($2.37)	-2.45

Notable Labs has higher revenue and earnings than COMPASS Pathways.

Institutional & Insider Ownership

70.5% of Notable Labs shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 1.2% of Notable Labs shares are held by company insiders. Comparatively, 4.3% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Notable Labs has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Notable Labs and COMPASS Pathways, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Notable Labs	0	0	2	0	3.00
COMPASS Pathways	0	0	5	0	3.00

Notable Labs currently has a consensus price target of $7.00, indicating a potential upside of 1,001.84%. COMPASS Pathways has a consensus price target of $47.40, indicating a potential upside of 715.83%. Given Notable Labs’ higher possible upside, research analysts clearly believe Notable Labs is more favorable than COMPASS Pathways.

Profitability

This table compares Notable Labs and COMPASS Pathways’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Notable Labs	N/A	-54.54%	-43.40%
COMPASS Pathways	N/A	-57.24%	-47.33%

Summary

Notable Labs beats COMPASS Pathways on 6 of the 9 factors compared between the two stocks.

About Notable Labs

Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.